Literature DB >> 28493006

Activity of Combined Antifungal Agents Against Multidrug-Resistant Candida glabrata Strains.

Laura Bedin Denardi1, Jéssica Tairine Keller2, Vanessa Oliveira2, Débora Alves Nunes Mario3, Janio Morais Santurio4, Sydney Hartz Alves5.   

Abstract

In this study, we evaluated the in vitro activity of echinocandins, azoles, and amphotericin B alone and in combination against echinocandin/azole-sensitive and echinocandin/azole-resistant Candida glabrata isolates. Susceptibility tests were performed using the broth microdilution method in accordance with the Clinical and Laboratory Standards Institute document M27-A3. The checkerboard method was used to evaluate the fractional inhibitory concentration index of the interactions. Cross-resistance was observed among echinocandins; 15% of the isolates resistant to caspofungin were also resistant to anidulafungin and micafungin. Synergistic activity was observed in 70% of resistant C. glabrata when anidulafungin was combined with voriconazole or posaconazole. Higher (85%) synergism was found in the combination of caspofungin and voriconazole. The combinations of caspofungin with fluconazole, posaconazole and amphotericin B, micafungin with fluconazole, posaconazole and voriconazole, and anidulafungin with amphotericin B showed indifferent activities for the majority of the isolates. Anidulafungin combined with fluconazole showed the same percentage of synergism and indifference (45%). Antagonism was detected in 50% of isolates when micafungin was combined with amphotericin B. Combinations of echinocandins and antifungal azoles have great potential for in vivo assays which are required to evaluate the efficacy of these combinations against multidrug-resistant C. glabrata strains.

Entities:  

Keywords:  Azoles; Candida glabrata; Combination therapy; Cross-resistance; Echinocandins

Mesh:

Substances:

Year:  2017        PMID: 28493006     DOI: 10.1007/s11046-017-0141-9

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  36 in total

1.  Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.

Authors:  M A Pfaller; M Castanheira; S R Lockhart; A M Ahlquist; S A Messer; R N Jones
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

2.  In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata.

Authors:  E R Oliveira; A W Fothergill; W R Kirkpatrick; B J Coco; T F Patterson; S W Redding
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

4.  Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Authors:  Santosh Katiyar; Michael Pfaller; Thomas Edlind
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

5.  Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections.

Authors:  Mariana Castanheira; Shawn A Messer; Ronald N Jones; David J Farrell; Michael A Pfaller
Journal:  Int J Antimicrob Agents       Date:  2014-07-23       Impact factor: 5.283

6.  Inflammatory response and clinical course of adult patients with nosocomial bloodstream infections caused by Candida spp.

Authors:  H Wisplinghoff; H Seifert; R P Wenzel; M B Edmond
Journal:  Clin Microbiol Infect       Date:  2006-02       Impact factor: 8.067

7.  Caspofungin in combination with amphotericin B against Candida glabrata.

Authors:  Francesco Barchiesi; Elisabetta Spreghini; Annette W Fothergill; Daniela Arzeni; Gianfranco Greganti; Daniele Giannini; Michael G Rinaldi; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

8.  Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.

Authors:  George R Thompson; Nathan P Wiederhold; Ana C Vallor; Nyria C Villareal; James S Lewis; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

9.  Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects.

Authors:  Nasrullah A Undre; Paul Stevenson; Darren Wilbraham
Journal:  Int J Clin Pharmacol Ther       Date:  2014-03       Impact factor: 1.366

10.  Candida spp. with acquired echinocandin resistance, France, 2004-2010.

Authors:  Eric Dannaoui; Marie Desnos-Ollivier; Dea Garcia-Hermoso; Fredéric Grenouillet; Sophie Cassaing; Marie-Thérèse Baixench; Stéphane Bretagne; Françoise Dromer; Olivier Lortholary
Journal:  Emerg Infect Dis       Date:  2012-01       Impact factor: 6.883

View more
  7 in total

1.  In Vitro Interaction of Geldanamycin with Triazoles and Echinocandins Against Common and Emerging Candida Species.

Authors:  Shahram Mahmoudi; Sassan Rezaie; Roshanak Daie Ghazvini; Seyed Jamal Hashemi; Hamid Badali; Alireza Foroumadi; Kambiz Diba; Anuradha Chowdhary; Jacques F Meis; Sadegh Khodavaisy
Journal:  Mycopathologia       Date:  2019-08-10       Impact factor: 2.574

2.  Diagnostic Aspects of Veterinary and Human Aspergillosis.

Authors:  Daniel Elad; Esther Segal
Journal:  Front Microbiol       Date:  2018-06-21       Impact factor: 5.640

3.  Coadministration of Ginger Extract and Fluconazole Shows a Synergistic Effect in the Treatment of Drug-Resistant Vulvovaginal Candidiasis.

Authors:  Arif Khan; Mohd Azam; Masood Alam Khan; Khaled S Allemailem; Faris Alrumaihi; Ahmad Almatroudi; Fahad A Alhumaydhi; Hafiz Iqtidar Ahmad; Masih Uzzaman Khan
Journal:  Infect Drug Resist       Date:  2021-04-21       Impact factor: 4.003

4.  Candida Isolates From Blood and Other Normally Sterile Foci From ICU Patients: Determination of Epidemiology, Antifungal Susceptibility Profile and Evaluation of Associated Risk Factors.

Authors:  Bo Wang; Xinlong He; Feng Lu; Yajuan Li; Yuerong Wang; Min Zhang; Ying Huang; Jinxing Xia
Journal:  Front Public Health       Date:  2021-11-11

5.  RPD3 and UME6 are involved in the activation of PDR5 transcription and pleiotropic drug resistance in ρ0 cells of Saccharomyces cerevisiae.

Authors:  Yoichi Yamada
Journal:  BMC Microbiol       Date:  2021-11-09       Impact factor: 3.605

Review 6.  Review on Plant-Based Management in Combating Antimicrobial Resistance - Mechanistic Perspective.

Authors:  Masita Arip; Malarvili Selvaraja; Mogana R; Lee Fang Tan; Mun Yee Leong; Puay Luan Tan; Vi Lien Yap; Sasikala Chinnapan; Ng Chin Tat; Maha Abdullah; Dharmendra K; Najwan Jubair
Journal:  Front Pharmacol       Date:  2022-09-29       Impact factor: 5.988

7.  Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?

Authors:  Alison R Novak; Mary E Bradley; Tyree H Kiser; Scott W Mueller
Journal:  Curr Fungal Infect Rep       Date:  2020-03-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.